DNA Methylation as a Biomarker of Treatment Response Variability in Serious Mental Illnesses: A Systematic Review Focused on Bipolar Disorder, Schizophrenia, and Major Depressive Disorder.

Main|Search|PHGKB




Last Posted: Oct 11, 2018

---

• DNA Methylation as a Biomarker of Treatment Response Variability in Serious Mental Illnesses: A Systematic Review Focused on Bipolar Disorder, Schizophrenia, and Major Depressive Disorder.
  Goud Alladi Charanraj et al. International journal of molecular sciences 2018 Oct 19(10)
• Companies Tout Psychiatric Pharmacogenomic Testing, But Is It Ready for a Store Near You?
  J Abbasi, JAMA, October 3, 2018
• In the race to use genetic tests to predict whether antidepressants will work, science might be getting left behind
  R Robbins, StatNews, September 28, 2018
• Overview of pharmacogenomic testing in clinical practice.
  Gross Tonya et al. The mental health clinician 2018 Sep 8(5) 235-241
• Richard Smith: Is precision medicine a fantasy?
  R Smith, BMJ Blog, July 13, 2018
• New Genetic Links to Depression May Pave the Way for Novel Treatment Strategies.
  Hampton Tracy et al. JAMA 2018 Jul 320(1) 20-21
• Modern molecular study of weight gain related to antidepressant treatment: clinical implications of the pharmacogenetic testing.
  Ageu Luminita Stefania et al. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2018 59(1) 165-173
• Cytochrome P450 genotype-guided drug therapies: an update on current states.
  Dong Amelia Nathania et al. Clinical and experimental pharmacology & physiology 2018 Jun
• Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients.
  Dong Olivia M et al. Pharmacogenomics 2018 May
• Clinical application of pharmacogenetics in pain management.
  Smith D Max et al. Personalized medicine 2018 Mar 15(2) 117-126

more